Department for Integrative Gastroenterology, Kliniken Essen-Mitte, University of Duisburg-Essen, Essen, Germany.
Aliment Pharmacol Ther. 2013 Sep;38(5):490-500. doi: 10.1111/apt.12397. Epub 2013 Jul 4.
The herbal treatment with myrrh, dry extract of chamomile flowers and coffee charcoal has anti-inflammatory and antidiarrhoeal potential and might benefit patients with UC. Aminosalicylates are used as standard treatment for maintaining remission in ulcerative colitis (UC).
To compare the efficacy of the two treatments in maintaining remission in patients with ulcerative colitis.
We performed a randomised, double-blind, double-dummy study over a 12-month period in patients with UC. Primary endpoint was non-inferiority of the herbal preparation as defined by mean Clinical Colitis Activity Index (CAI-Rachmilewitz). Secondary endpoints were relapse rates, safety profile, relapse-free times, endoscopic activity and faecal biomarkers.
A total of 96 patients (51 female) with inactive UC were included. Mean CAI demonstrated no significant difference between the two treatment groups in the intention-to-treat (P = 0.121) or per-protocol (P = 0.251) analysis. Relapse rates in total were 22/49 patients (45%) in the mesalazine treatment group and 25/47 patients (53%) in the herbal treatment group (P = 0.540). Safety profile and tolerability were good and no significant differences were shown in relapse-free time, endoscopy and faecal biomarkers.
The herbal preparation of myrrh, chamomile extract and coffee charcoal is well tolerated and shows a good safety profile. We found first evidence for a potential efficacy non-inferior to the gold standard therapy mesalazine, which merits further study of its clinical usefulness in maintenance therapy of patients with ulcerative colitis. EudraCT-Number 2007-007928-18.
没药、甘菊花朵干提取物和咖啡炭的草药疗法具有抗炎和止泻作用,可能有益于溃疡性结肠炎(UC)患者。氨基水杨酸类药物被用作溃疡性结肠炎缓解期的标准治疗方法。
比较两种治疗方法在维持溃疡性结肠炎患者缓解期的疗效。
我们在患有溃疡性结肠炎的患者中进行了为期 12 个月的随机、双盲、双模拟研究。主要终点是根据临床结肠炎活动指数(CAI-Rachmilewitz)均值定义的草药制剂的非劣效性。次要终点是复发率、安全性概况、无复发时间、内镜活动和粪便生物标志物。
共纳入 96 例(51 例女性)活动性 UC 患者。意向治疗(P=0.121)或方案治疗(P=0.251)分析均显示,两组间平均 CAI 无显著差异。在总复发率方面,美沙拉嗪治疗组 49 例患者中有 22 例(45%)复发,草药治疗组 47 例患者中有 25 例(53%)复发(P=0.540)。安全性和耐受性良好,无复发时间、内镜和粪便生物标志物方面无显著差异。
没药、甘菊提取物和咖啡炭的草药制剂具有良好的耐受性,且安全性良好。我们首次发现其疗效可能不劣于金标准疗法美沙拉嗪,值得进一步研究其在溃疡性结肠炎维持治疗中的临床应用。EudraCT-编号 2007-007928-18。